Hitting the Bull’s-Eye: Mesothelin’s Role as a Biomarker and Therapeutic Target for Malignant Pleural Mesothelioma

Hitting the Bull’s-Eye: Mesothelin’s Role as a Biomarker and Therapeutic Target for Malignant Pleural Mesothelioma.

Full text not available from this repository.
Item Type: Review
Status: Published
Official URL: https://doi.org/10.3390/cancers13163932
Journal or Publication Title: Cancers
Volume: 13
Number: 16
Page Range: p. 3932
Date: 4 August 2021
Divisions: Gene and Stem Cell Therapy
Depositing User: General Admin
Identification Number: 10.3390/cancers13163932
ISSN: 2072-6694
Date Deposited: 10 Oct 2021 10:46

Malignant pleural mesothelioma (MPM) is an aggressive cancer with limited treatment options and poor prognosis. MPM originates from the mesothelial lining of the pleura. Mesothelin (MSLN) is a glycoprotein expressed at low levels in normal tissues and at high levels in MPM. Many other solid cancers overexpress MSLN, and this is associated with worse survival rates. However, this association has not been found in MPM, and the exact biological role of MSLN in MPM requires further exploration. Here, we discuss the current research on the diagnostic and prognostic value of MSLN in MPM patients. Furthermore, MSLN has become an attractive immunotherapy target in MPM, where better treatment strategies are urgently needed. Several MSLN-targeted monoclonal antibodies, antibody-drug conjugates, immunotoxins, cancer vaccines, and cellular therapies have been tested in the clinical setting. The biological rationale underpinning MSLN-targeted immunotherapies and their potential to improve MPM patient outcomes are reviewed.

Keywords: CAR T cells; biomarker; cancer; immunotherapy; malignant mesothelioma; malignant pleural mesothelioma; mesothelin; therapeutic target.

Yeo, Dannel
Castelletti, Laura
van Zandwijk, Nico
Rasko, John E. J.
Last Modified: 10 Oct 2021 10:46
URI: https://eprints.centenary.org.au/id/eprint/1084

Actions (login required)

View Item View Item